BIIB105
RNA / oligonucleotide
Also known as ION541
Evidence outlook
Development stopped: Phase 1/2 study terminated
The drug's registered studies are all terminated, withdrawn or suspended (NCT04494256: terminated); none completed, so no evidence signal is assigned. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ALSpire NCT04494256 · Amyotrophic Lateral Sclerosis Part 1 randomly assigned participants to BIIB105 or placebo under blinding with a real placebo comparator, but the primary outcome reported is only adverse-event counts rather than a disease-efficacy comparison, and the smallest dose cohorts enrolled as few as 6 participants. Efficacy measures such as functional decline and survival were collected but no comparative results are available in this record, and the open-label extension was stopped early by the sponsor. Its registered primary outcome on ClinicalTrials.gov is "Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT04494256 | 1/2 | Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) (From first dose of the study drug in Part 1 up to end of follow up period in Part 1 (up to Day 260)); Part 2: Number of Participants With TEAEs and TESAEs (From first dose of the study in Part 2 up to end of follow up period in Part 2 (up to Day 1184)) 2024-08-13 | Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) (From first dose of the study drug in Part 1 up to end of follow up period in Part 1 (up to Day 260)): Part 1: Pooled Placebo 1+2 — TEAEs: 28 Participants; TESAEs: 5 Participants | Part 1: Cohort A: BIIB105 5 mg — TEAEs: 6 Participants; TESAEs: 0 Participants | Part 1: Cohort B: BIIB105 20 mg — TEAEs: 6 Participants; TESAEs: 0 Participants | Part 1: Cohorts C1+C2: BIIB105 60 mg — TEAEs: 11 Participants; TESAEs: 1 Participants | Part 1: Cohorts D1 + D2: BIIB105 120 mg — TEAEs: 48 Participants; TESAEs: 7 Participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
Other ATXN2 (ataxin-2) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| BIIB105: this drug | Phase 1/2 | RNA / oligonucleotide | Ataxin-2 (ATXN2) mRNA, ATXN2 (ataxin-2) | Weak signal | Featured results are safety only | |
| SRP-1004 | Phase 1(overall) | RNA / oligonucleotide | ATXN2 (ataxin-2) | not yet graded | No reviewed efficacy summary |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent